{"id":5424,"date":"2025-12-29T12:10:36","date_gmt":"2025-12-29T12:10:36","guid":{"rendered":"https:\/\/network.rvrising.com\/?p=5424"},"modified":"2025-12-29T12:10:36","modified_gmt":"2025-12-29T12:10:36","slug":"nuvalent-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.rvrising.com\/news\/business\/nuvalent-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<p><span class=\"legendSpanClass\">CAMBRIDGE, Mass.<\/span>, <span class=\"legendSpanClass\">Dec. 22, 2025<\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/www.nuvalent.com\/\" target=\"_blank\" rel=\"nofollow noopener\">Nuvalent, Inc.<\/a>\u00a0(Nasdaq: <a class=\"ticket-symbol\" href=\"#financial-modal\" data-toggle=\"modal\">NUVL<\/a>), a clinical-stage biopharmaceutical company focused on creating\u00a0<i>precisely<\/i>\u00a0targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 44<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on\u00a0Tuesday, January 13, 2026, at\u00a09:00 a.m. PT\u00a0in San Francisco.<\/p>\n<div>\n<p>A live webcast will be available in the Investors section of the company&#8217;s website at\u00a0<a href=\"http:\/\/www.nuvalent.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.nuvalent.com<\/a>, and archived for 30 days following the presentation.<\/p>\n<p><b>About Nuvalent<br class=\"dnr\" \/><\/b>Nuvalent, Inc. (Nasdaq: <a class=\"ticket-symbol\" href=\"#financial-modal\" data-toggle=\"modal\">NUVL<\/a>) is a clinical-stage biopharmaceutical company focused on creating\u00a0<i>precisely<\/i>\u00a0targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.<\/p>\n<p>SOURCE Nuvalent, Inc.<\/p>\n<\/div>\n<p><b>This release is auto-published via PR Newswire; our journal is not responsible for the content.<\/b><\/p>\n<p><a href=\"https:\/\/www.prnewswire.com\/news-releases\/nuvalent-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302647193.html\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Dec. 22, 2025 \/PRNewswire\/ &#8212;\u00a0Nuvalent, Inc.\u00a0(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating\u00a0precisely\u00a0targeted therapies for<\/p>\n","protected":false},"author":1,"featured_media":5425,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8,92],"tags":[],"class_list":["post-5424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-pr-newswire"],"_links":{"self":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/5424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/comments?post=5424"}],"version-history":[{"count":1,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/5424\/revisions"}],"predecessor-version":[{"id":5560,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/posts\/5424\/revisions\/5560"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media\/5425"}],"wp:attachment":[{"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/media?parent=5424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/categories?post=5424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rvrising.com\/news\/wp-json\/wp\/v2\/tags?post=5424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}